Valneva SE (NASDAQ:VALN - Get Free Report) saw a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 4,800 shares, a decline of 27.3% from the April 30th total of 6,600 shares. Currently, 0.0% of the company's stock are short sold. Based on an average daily volume of 78,300 shares, the days-to-cover ratio is currently 0.1 days.
Analyst Ratings Changes
VALN has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim cut their target price on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th.
Read Our Latest Analysis on Valneva
Valneva Stock Up 1.7%
NASDAQ:VALN traded up $0.11 during trading hours on Thursday, hitting $6.36. 4,408 shares of the stock traded hands, compared to its average volume of 42,265. The firm has a 50 day moving average price of $6.51 and a 200 day moving average price of $5.85. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $8.99. The firm has a market cap of $531.51 million, a price-to-earnings ratio of -48.88 and a beta of 1.81.
Valneva (NASDAQ:VALN - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.27. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. The company had revenue of $51.79 million for the quarter, compared to the consensus estimate of $41.80 million. Equities research analysts anticipate that Valneva will post 0.13 earnings per share for the current year.
Hedge Funds Weigh In On Valneva
A number of hedge funds have recently modified their holdings of VALN. ABC Arbitrage SA acquired a new position in shares of Valneva in the fourth quarter worth $84,000. Wells Fargo & Company MN increased its stake in shares of Valneva by 14.3% in the fourth quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after acquiring an additional 30,859 shares during the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of Valneva in the first quarter worth $94,000. 11.39% of the stock is owned by institutional investors and hedge funds.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
See Also
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
